Vigil Neuroscience Inc (VIGL) Receives a Buy from Stifel Nicolaus

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report), with a price target of $11.00. The company’s shares closed last Friday at $2.64.

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

According to TipRanks, Matteis is a 3-star analyst with an average return of 0.8% and a 39.90% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neurocrine, Vertex Pharmaceuticals, and Neurogene.

Vigil Neuroscience Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.53.

The company has a one-year high of $6.06 and a one-year low of $1.49. Currently, Vigil Neuroscience Inc has an average volume of 1.07M.